Drug Trial Radar · NCT06962007
Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal
Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
Sep 20, 2026
Study completion Oct 14, 2026
Sponsor
- Lead sponsor
- Wonkwang University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 8, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study Objective: This study aims to evaluate the incidence, severity, and risk factors of sugammadex-induced mouth clenching during neuromuscular blockade (NMB) reversal in adult surgical patients. Study Design: This prospective, randomized, double-blind, controlled clinical trial enrolls adult patients (ASA physical status I-II, aged 19-70 years) undergoing elective surgery under general anesthesia with rocuronium. Patients will be randomized into four groups to receive either sugammadex at doses of 1 mg/kg, 2 mg/kg, or 4 mg/kg, or a combination of pyridostigmine and glycopyrrolate. Primary Outcome: The primary outcome is the incidence of clenching within 10 minutes after NMB reversal, assessed by clinical observation, masseter EMG, and airway pressure changes, using a novel five-grade severity scale. Secondary Outcomes: Secondary outcomes include the severity of clenching, time to TOF ratio ≥0.9, BIS values at clenching onset, complications, and identification of risk factors such as dose, sex, BIS, age, BMI, and rocuronium dose. Significance: This study seeks to improve perioperative safety by identifying modifiable risk factors and informing dose adjustments or alternative reversal strategies to prevent sugammadex-induced clenching, particularly in high-risk populations.
Conditions
- Neuromuscular Blockade Reversal Agent
- Perioperative Complications
- Anesthesia, General
- Sugammadex
- Monitoring, Intraoperative
- Masseter Muscle Spasm
Interventions
Sugammadex 1 mg/kg GroupDrug
Participants receive 1 mg/kg of sugammadex intravenously for reversal of rocuronium-induced neuromuscular blockade.
Sugammadex 2 mg/kg GroupDrug
Participants receive 2 mg/kg of sugammadex intravenously for reversal of rocuronium-induced neuromuscular blockade.
Sugammadex 4 mg/kg GroupDrug
Participants receive 4 mg/kg of sugammadex intravenously for reversal of rocuronium-induced neuromuscular blockade.
Pyridostigmine/Glycopyrrolate GroupDrug
Participants receive pyridostigmine 0.2 mg/kg and glycopyrrolate 0.01 mg/kg intravenously for reversal of rocuronium-induced neuromuscular blockade.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Mouth Clenching After Neuromuscular Blockade ReversalTime frame: Within 10 minutes after administration of neuromuscular blockade reversal agent
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Wonkwang University hospital
Iksan, Jeonbuk-do, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.